Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135773 | 0.89 | CYP11B1 (0.37) | HRH3KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL4142343 | 0.89 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL4140206 | 0.89 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL4142298 | 0.88 | HRH3 (0.39) | HRH3KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL4141039 | 0.88 | HRH3 (0.45) | HRH3KCNH2OPRM1 | |
| SCHEMBL4147612 | 0.87 | HRH3 (0.43) | HRH3KCNH2 | |
| SCHEMBL4139788 | 0.86 | CYP11B2 (0.39) | HRH3KCNH2DRD2 | |
| SCHEMBL4129121 | 0.86 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL4139793 | 0.86 | CYP11B2 (0.39) | HRH3KCNH2DRD2 | |
| SCHEMBL4136956 | 0.85 | HRH3 (0.38) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 657/4885OPRK1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.